Table 2

Clinical response after 12 months for both tapering groups, according to intention-to-treat

Clinical response after 12 monthsTapering csDMARD (n=85)Tapering TNF inhibitor (n=89)
Disease activity
 DAS44, mean (95% CI)1.31 (1.17 to 1.46)1.35 (1.19 to 1.51)
 TJC44, median (IQR)0 (0–2)0 (0–3)
 SJC44, median (IQR)0 (0–0)0 (0–1)
 VAS disease activity (0–100 mm), median (IQR)17 (5–36)19 (6–42)
 ESR in mm/hour, median (IQR)11 (5–21)11 (4–19)
 CRP in mg/L, median (IQR)2.9 (1–6)4 (1–9)
 DAS clinical remission, DAS44 <1.6, n (%)57 (69)58 (66)
 ΔDAS44 (T12–T0), mean (95% CI)0.28 (0.16 to 0.40)0.40 (0.22 to 0.57)
Radiographic progression (hand/foot)
 mTSS (0–488), median (IQR)2 (0–6.5)1 (0–4)
 Erosion score (0–280), median (IQR)0.5 (0–2)0 (0–2)
 JSN score (0–168), median (IQR)0.5 (0–2.5)0 (0–2.5)
 ΔmTSS (T12–T0), median (IQR)0 (0–0)0 (0–0)
 Patients with progression >0.5, n (%)4 (5)5 (6)
 Patients with progression >0.9, n (%)4 (5)5 (6)
 Erosive disease, n(%)*37 (44)30 (34)
Patient-reported outcomes
 HAQ-DI, mean (95% CI)0.59 (0.46 to 0.73)0.55 (0.43 to 0.66)
 ΔHAQ-DI (T12-T0), mean (95% CI)0.05 (-0.05 to 0.13)0.07 (-0.01 to 0.16)
 SF-36, median (IQR)
  PCS43 (32–50)44 (35–50)
  MCS58 (53–62)59 (51–62)
 EQ-5D index, mean (95% CI)0.80 (0.76 to 0.84)0.82 (0.79 to 0.85)
 ΔEQ-5D index (T12–T0), mean (95% CI)−0.06 (-0.09 to 0.02)−0.05 (-0.08 to 0.02)
  • *Erosive disease is characterised as having >1 erosion in three separate joints.

  • . JSN; Joint space narrowing, CRP, C reactive protein;DAS44, Disease Activity Score Measured in 44 joints;EQ-5D, European Quality of Life-5 Dimensions;ESR, erythrocyte sedimentation rate;HAQ-DI, Health Assessment Questionnaire Disability Index;MCS, mental component summary;PCS, physical component summary;SF-36, Short Form-36 ; SJC, Swollen Joint Count;TJC, Tender Joint Count;TNF, tumor necrosis factor; VAS, Visual Analogue Scale; csDMARD, conventional synthetic disease-modifying antirheumatic drug;mTSS, modified Sharp/Van der Heijde score.